IP Library Granted Patent US 9,187,732
Granted Patent B2
US 9,187,732 · App. 14/049,601 · Granted Nov 17, 2015

Replication deficient influenza virus for the expression of heterologous sequences

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,732
App. No.
14/049,601
Granted
Nov 17, 2015
Kind
B2
Abstract

The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.

Claims (22)

1. A replication deficient influenza virus, characterized in that the virus comprises:

a) a modified NS segment coding for a NS1 protein comprising at least one amino acid modification within positions 1 to 73 resulting in a complete lack of functional RNA binding and at least one amino acid modification between position 74 and the carboxy-terminal amino acid residue resulting in a complete lack of effector function, and

b) a heterologous sequence between a functional splice donor site and a functional splice acceptor site inserted in the NS gene segment,

wherein the virus comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:78, and SEQ ID NO:79.

2. A replication deficient influenza virus according to claim 1 , further comprising a signal peptide or part thereof fused to the C-terminus of NS1 protein.

3. A replication deficient influenza virus according to claim 1 , wherein the virus further comprises a lariat consensus sequence upstream of the splice acceptor site.

4. A replication deficient influenza virus according to claim 1 , wherein the virus is formulated as a vaccine.

5. A vector comprising a nucleotide sequence coding for a replication deficient influenza virus according to claim 1 .

6. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:1.

7. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:2.

8. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:3.

9. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:4.

10. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:5.

11. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:6.

12. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:7.

13. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:8.

14. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:9.

15. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:10.

16. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:67.

17. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:68.

18. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:78.

19. A replication deficient influenza virus according to claim 1 , wherein the virus comprises SEQ ID NO:79.

Assignments (8)
CHANGE OF NAME Recorded Nov 20, 2025
From: RESILIENCE GOVERNMENT SERVICES, INC,
To: ALACHUA GOVERNMENT SERVICES, INC.
Reel/Frame 073279/0021 →
CHANGE OF NAME Recorded Sep 8, 2022
From: OLOGY BIOSERVICES, INC.
To: RESILIENCE GOVERNMENT SERVICES, INC.
Reel/Frame 061399/0903 →
RELEASE OF SECURITY INTEREST Recorded Aug 20, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: OLOGY BIOSERVICES, INC.; NANO ADM, LLC
Reel/Frame 053561/0070 →
CHANGE OF NAME Recorded Jan 23, 2019
From: NANOTHERAPEUTICS, INC.
To: OLOGY BIOSERVICES, INC.
Reel/Frame 048117/0275 →
SECURITY INTEREST Recorded May 1, 2018
From: OLOGY BIOSERVICES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046050/0305 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRESPONDENCE DATA PREVIOUSLY RECORDED ON REEL 037155 FRAME 0732. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 2, 2016
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 038592/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2015
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 037155/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH
Reel/Frame 036388/0729 →